GR3004199T3 - - Google Patents

Info

Publication number
GR3004199T3
GR3004199T3 GR920400570T GR920400570T GR3004199T3 GR 3004199 T3 GR3004199 T3 GR 3004199T3 GR 920400570 T GR920400570 T GR 920400570T GR 920400570 T GR920400570 T GR 920400570T GR 3004199 T3 GR3004199 T3 GR 3004199T3
Authority
GR
Greece
Prior art keywords
cyclosporins
cyclodextrin
fungal
admixture
rendered
Prior art date
Application number
GR920400570T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3004199T3 publication Critical patent/GR3004199T3/el

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GR920400570T 1987-06-04 1992-03-31 GR3004199T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14070387 1987-06-04

Publications (1)

Publication Number Publication Date
GR3004199T3 true GR3004199T3 (enExample) 1993-03-31

Family

ID=15274767

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920400570T GR3004199T3 (enExample) 1987-06-04 1992-03-31

Country Status (10)

Country Link
US (1) US5051402A (enExample)
EP (1) EP0294239B1 (enExample)
JP (1) JP2577049B2 (enExample)
AT (1) ATE72629T1 (enExample)
AU (1) AU607506B2 (enExample)
CA (1) CA1325973C (enExample)
DE (1) DE3868438D1 (enExample)
ES (1) ES2033429T3 (enExample)
GR (1) GR3004199T3 (enExample)
HK (1) HK28097A (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH07111785B2 (ja) 1990-01-19 1995-11-29 富士通株式会社 光ディスク
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
FR2670629B1 (fr) * 1990-12-17 1995-03-10 Moving Magnet Tech Actionneur electromagnetique monophase rotatif.
ATE158022T1 (de) * 1991-01-25 1997-09-15 Fujisawa Pharmaceutical Co Prozess zur produktion von cyclosporin-a und/oder c
DK0642332T3 (da) * 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
DK0756489T3 (da) * 1994-06-01 1999-12-06 Yuhan Corp Cyclosporinholdigt præparat og fremgangsmåde til fremstillingen af dette
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
JP2007056045A (ja) * 1995-05-26 2007-03-08 Nobaruteisu Fuaama Kk サイクロデキストリン組成物
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
KR20040004416A (ko) 1997-01-30 2004-01-13 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 a 함유 제약 조성물
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
DK0991660T3 (da) 1997-10-08 2006-02-13 Isotechnika Inc Deuterede og udeuterede cyclosporinanaloger og deres anvendelse som immunmodulerende midler
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US7141648B2 (en) 2001-10-19 2006-11-28 Isotechnika Inc. Synthesis of cyclosporin analogs
CA2461730C (en) * 2001-10-19 2012-05-15 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
RU2006121978A (ru) 2003-11-21 2007-12-27 Комбинаторкс, Инкорпорейтед (Us) Способы и реагенты для лечения воспалительных нарушений
US7691812B2 (en) * 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
MX338355B (es) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
ES2780182T3 (es) * 2011-06-29 2020-08-24 Allergan Inc Formulaciones de 15-hidroxiestearato de macrogol
CN108024951A (zh) * 2015-05-29 2018-05-11 奥库里斯公司 环孢菌素a/环糊精纳米颗粒的形成
CN105997863B (zh) * 2016-07-21 2018-09-04 河南省眼科研究所 环孢素a滴眼液及其制备方法
IL310360A (en) 2016-11-29 2024-03-01 Oculis Operations Sarl Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP4670738A2 (en) 2019-07-01 2025-12-31 Oculis Operations Sàrl METHOD FOR STABILIZING THE pH OF AN AQUEOUS COMPOSITION COMPRISING A MEDICINE
CN112724200B (zh) * 2019-10-28 2022-09-27 上海云泽生物科技有限公司 一种稳定环孢霉素a的稀释液及其应用
JP2023548966A (ja) 2020-11-09 2023-11-21 スカイ・セラピューティクス・カンパニー・リミテッド 固相のシクロスポリンa及びこれを含む分散組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
AU558155B2 (en) * 1982-02-01 1987-01-22 Sandoz Ltd. Treating multiple sclerosis with dihydro-cyclosporin d
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
EP0170623B1 (en) * 1984-08-02 1990-11-28 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine

Also Published As

Publication number Publication date
US5051402A (en) 1991-09-24
ES2033429T3 (es) 1993-03-16
AU607506B2 (en) 1991-03-07
EP0294239B1 (en) 1992-02-19
JP2577049B2 (ja) 1997-01-29
CA1325973C (en) 1994-01-11
EP0294239A1 (en) 1988-12-07
JPS6485921A (en) 1989-03-30
DE3868438D1 (de) 1992-03-26
ATE72629T1 (de) 1992-03-15
AU1738688A (en) 1988-12-22
HK28097A (en) 1997-03-06

Similar Documents

Publication Publication Date Title
GR3004199T3 (enExample)
GR3005454T3 (enExample)
IT1232243B (it) Composizioni farmaceutiche a base di ciclosporine
MY102660A (en) Therapeutic system for sparingly soluble active ingredients
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
CA2004451A1 (en) Enossal implant
ES2065906T3 (es) Produccion de proteinas en formas activas.
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
WO1991015512A3 (en) Hiv envelope polypeptides
EP0259982A3 (en) Solid iodophor composition
RU96114157A (ru) Способ лечения острых отравлений
DE3867086D1 (de) Benzothiepino(5,4-c)pyridazin-verbindungen und ihre pharmazeutischen wirkungen.
GR3004303T3 (enExample)
JPS6485990A (en) Antihypertestoeronemia agent
ATE60231T1 (de) Unloesliches arzneimittel das lokal im ohr verabreicht wird.
JPS6461429A (en) Remedy for cancer
NO893925L (no) 1-metyl-3, 5, 7-triaza-1-azoniatricyklodekan trijodid, fremgangsmaate for fremstilling derav, og anvendelse derav ved bekjempelse av mikroorganismer i vandige systemer.
Seo Recommendations for the Improvement of the Medical Licensing Examination
IT1238692B (it) Composizioni farmaceutiche a base di calcitonina per la somministrazione sublinguale
IT8723080A0 (it) Componente d'arredamento, in particolare del tipo poltrona o simile.
JPS6429320A (en) Drug composition
IT1203917B (it) Farmacologicamente attivi. derivati dell'1,2,4-triazolo
IT8620504A0 (it) Derivati dell'1,2,4-triazolo farmacologicamente attivi.
MX6414A (es) Pirrolo[1,2-a] [4,1]benzoxazepinas y procedimientopara su preparacion.
ATE100814T1 (de) 19-nor-progesteron-derivate, ihre herstellung und anwendung.